The following is an interview with Dr Tanya Dorff, Associate Clinical Professor; Head, GU Cancer Program, City of Hope Hospital, California, where she discusses a potential role for high dose interleukin 2 (IL2) for the treatment of metastatic renal cell carcinoma (mRCC). The study that Dr Dorff talks about was presented at the American Society of Clinical Oncology Genitourinary (ASCO GU) 2018 conference in San Francisco last week.

See Dr Dorff’s interview on Practice Update here